Hepatocyte growth factor levels are associated with the results of 123I-metaiodobenzylguanidine myocardial scintigraphy in patients with type 2 diabetes mellitus

Metabolism: Clinical and Experimental

Volumn 58, Issue 2, 2009, Pages 167-173

  Anan, Futoshi ^a,b   Masaki, Takayuki ^b   Yonemochi, Hidetoshi ^b   Takahashi, Naohiko ^b   Nakagawa, Mikiko ^b   Eshima, Nobuoki ^c   Saikawa, Tetsunori ^b   Yoshimatsu, Hironobu ^b  

^a OITA RED CROSS HOSPITAL   (Japan)

^b OITA UNIVERSITY   (Japan)

^c OITA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 123; ALPHA GLUCOSIDASE INHIBITOR; ANGIOTENSIN RECEPTOR ANTAGONIST; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; NORADRENALIN; PIOGLITAZONE; SCATTER FACTOR; SULFONYLUREA DERIVATIVE;

ADULT; ARTICLE; AUTONOMIC NERVOUS SYSTEM FUNCTION; AUTONOMIC NEUROPATHY; BODY COMPOSITION; CARDIOVASCULAR DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE DURATION; DYSLIPIDEMIA; ECHOCARDIOGRAPHY; FEMALE; HEART RATE VARIABILITY; HEART SCINTISCANNING; HUMAN; HYPERTENSION; IMAGING SYSTEM; INSULIN RESISTANCE; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; NORADRENALIN BLOOD LEVEL; PRIORITY JOURNAL; SCINTILLATION CAMERA; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

3-IODOBENZYLGUANIDINE; AGED; ASIAN CONTINENTAL ANCESTRY GROUP; AUTONOMIC NERVOUS SYSTEM DISEASES; DIABETES MELLITUS, TYPE 2; ECHOCARDIOGRAPHY; FEMALE; HEART; HEART DISEASES; HEPATOCYTE GROWTH FACTOR; HUMANS; INSULIN RESISTANCE; MALE; MIDDLE AGED; MYOCARDIAL PERFUSION IMAGING; PREDICTIVE VALUE OF TESTS; REGRESSION ANALYSIS;

EID: 58249091457     PISSN: 00260495     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.metabol.2008.09.009     Document Type: Article

References (39)

1. Morishita R., Moriguchi A., Higaki J., et al. Hepatocyte growth factor (HGF) as a potential index of severity of hypertension. Hypertens Res 22 (1999) 161-167
2. Yamamoto K., Morishita R., and Hayashi S. Contribution of Bcl-2, but not Bcl-xL and Bax, to antiapoptotic actions of hepatocyte growth factor in hypoxia-conditioned human endothelial cells. Hypertension 37 (2001) 1341-1348
3. Hayashi K., Nakamura S., and Morishita R. In vivo transfer of human hepatocyte growth factor gene accelerates re-endothelialization and inhibits neointimal formation after balloon injury in rat model. Gene Therapy 7 (2000) 1664-1671
4. Hayashi Y., Saitoh S., and Takagi S. Hepatocyte growth factor and 24-hour ambulatory blood pressure monitoring. Hypertens Res 25 (2002) 655-660
5. Satani K., Konya H., Hamaguchi T., et al. Clinical significance of circulating hepatocyte growth factor, a new risk marker of carotid atherosclerosis in patients with type 2 diabetes. Diabetic Med 23 (2006) 617-622
6. Hata N., Matsumori A., Yokoyama S., et al. Hepatocyte growth factor and cardiovascular thrombosis in patients admitted to the intensive care unit. Cir J 68 (2004) 645-649
7. Matsumori A., Takano H., and Obata J. Circulating hepatocyte growth factor as a diagnostic marker of thrombus formation in patients with cerebral infarction. Cir J 66 (2002) 216-218
8. Malatino L.S., Cataliotti A., Benedetto F.A., et al. Hepatocyte growth factor and left ventricular geometry in end stage renal disease. Hypertension 41 (2003) 88-92
9. Tsuji H., Larson M.G., and Venditti Jr. F.J. Impact of reduced heart rate variability on risk for cardiac events. The Framingham Study. Circulation 94 (1996) 2850-2855
10. La Rovere M.T., Bigger Jr. J.T., Marcus F.I., et al. Baroreflex sensitivity and heart-rate variability in prediction of total cardiac mortality after myocardial infraction. ATRAMI (Autonomic Tone and Reflexes After Myocardial Infraction) Investigators. Lancet 351 (1998) 478-484
11. Reichard P., and Pihl M. Mortality and treatment side-effects during long-term intensified conventional insulin treatment in the Stockholm Diabetes Intervention Study. Diabetes 43 (1994) 313-317
12. Takahashi N., Nakagawa M., and Saikawa T. Effect of essential hypertension on cardiac autonomic function in type 2 diabetic patients. J Am Coll Cardiol 38 (2001) 232-237
13. 123I-metaiodobenzylguanidine myocardial scintigraphy in type 2 diabetic patients. Eur J Nucl Med Mol Imaging 34 (2007) 28-35
14. 123I-metaiodobenzylguanidine myocardial scintigraphy in type 2 diabetic patients. Eur J Nucl Med Mol Imaging 34 (2007) 1189-1197
15. Hiratsuka A., Adachi H., Fujiura Y., et al. Strong association between serum hepatocyte growth factor and metabolic syndrome. J Clin Endocrinol Metab 90 (2005) 2927-2931
16. Gerritsen J., TenVoorde B.J., Dekker J.M., et al. Measures of cardiovascular autonomic dysfunction nervous function: agreement, reproducibility, and reference values in middle age and elderly subjects. Diabetologia 46 (2003) 330-338
17. 123I-MIBG. J Nucl Med 40 (1999) 6-11
18. Spallone V., and Menzinger G. Diagnosis of cardiovascular autonomic neuropathy in diabetes. Diabetes 46 (1997) S67-S76
19. Watanabe K., Sekiya M., Tsuruoka T., et al. Relationship between insulin resistance and cardiac sympathetic nervous function in essential hypertension. J Hypertens 17 (1999) 1161-1168
20. Tsubouchi H., Niitani Y., and Hirono S. Levels of human hepatocyte growth factor in serum of patients with liver disease determined by an enzyme-linked immunosorbent assay. Hepatology 13 (1991) 1-5
21. Tanigawa N., Segawa Y., Maeda Y., et al. Serum hepatocyte growth factor/scatter factor levels in small cell lung cancer patients. Lung Cancer 7 (1997) 211-218
22. Mancia G., De Backer G., Dominiczak A., et al. 07 ESH-ESC practice guidelines for the management of arterial hypertension: ESH-ESC task force on the management of arterial hypertension. J Hypertens 25 (2007) 1751-1762
23. Matthews D.R., Hosker J.P., Rudenski A.S., et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28 (1985) 412-419
24. Sato T., Nishinaga M., Kawamoto A., et al. Accuracy of a continuous blood pressure monitor based on arterial tonometry. Hypertension 21 (1993) 866-874
25. Milliani A., Pagani M., Lombardi F., et al. Cardiovascular neural regulation explored in the frequency domain. Circulation 84 (1991) 482-492
26. Bell L.N., Ward J.L., Degawa-Yamauchi M., et al. Adipose tissue production of hepatocyte growth factor contributes to elevated serum HGF in obesity. Am J Physiol Endocrinol Metab 291 (2006) E843-E848
27. Hotamisligil G.S., Arner P., Caro J.F., et al. Increased adipose tissue expression of tumor necrosis factor-α in human obesity and insulin resistance. J Clin Invest 95 (1995) 2409-2415
28. Katsuki A., Sumida Y., Murashima S., et al. Serum levels of tumor necrosis factor-α are increased in obese patients with noninsulin-dependent diabetes mellitus. Clin Endocrinol Metab 83 (1998) 859-862
29. Kinjyo Y., Kajiyama S., Fujiwara H., et al. Influence of the polyol pathway on transporter reduction in diabetic cardiac sympathetic nerve: implication for heterogeneous accumulation of MIBG. Eur J Nucl Med Mol Imaging 32 (2005) 438-442
30. Schofer J., Spielmann R., Schuchert A., et al. Iodine-123 metaiodobenzylguanidine scintigraphy a noninvasive method to demonstrate myocardial adrenergic nerve system disintegrity in patients with idiopathic dilated cardiomyopathy. J Am Coll Cardiol 12 (1988) 1252-1258
31. Imamura Y., Ando H., Mitsuoka W., et al. Iodine-123 metaiodobenzylguanidine images reflect intense myocardial adrenergic nervous activity in congestive heart failure independent of underlying cause. J Am Coll Cardiol 26 (1995) 1594-1599
32. Nagamachi S., Fujita S., Nishii R., et al. Prognostic value of cardiac I-123 metaiodobenzylguanidine images in patients with non-insulin-dependent diabetes mellitus. J Nucl Cardiol 13 (2006) 34-42
33. 123I] metaiodobenzylguanidine. Diabetes 41 (1992) 1069-1075
34. Meigs J., Jacques P.F., Selhub J., et al. Framingham Offspring Study. Fasting plasma homocysteine levels in the insulin resistance syndrome. The Framingham Offspring study. Diabetes Care 24 (2001) 1403-1410
35. Ma H., Cadleron T.M., Fallon J.T., et al. Hepatocyte growth factor is a survival factor for endothelial cells and is expressed in human atherosclerotic plaques. Atherosclerosis 164 (2002) 79-87
36. Rehman J., Considine R.V., Bovenkerk J.E., et al. Obesity is associated with increased levels of circulating hepatocyte growth factor. J Am Coll Cardiol 41 (2003) 1408-1413
37. 2+- and phosphoinositide 3-kinase/AKT-dependent phosphorylation in aortic endothelial cells. Biochem J 374 (2003) 63-69
38. Watanabe K., Sekiya M., Tsuruoka T., et al. Effect of insulin resistance on left ventricular hypertrophy and dysfunction in essential hypertension. J Hypertens 17 (1999) 1153-1160
39. Yamashina S., and Yamazaki J. Role of MIBG myocardial scintigraphy in the assessment of heart failure: the need to establish evidence. Eur J Nucl Med Mol Imaging 31 (2004) 1353-1355